Send Message
Home News

company news about Dapagliflozin Approved For Chronic Kidney Disease Indications

Certification
China Wuhan Senwayer Century Chemical Co., Ltd. certification
China Wuhan Senwayer Century Chemical Co., Ltd. certification
Customer Reviews
everything was great. friendly and understanding representative and fast shipping(compared to other items on here). my shoulder feels much stronger and healthier after only one and a half weeks.

—— Terry Smith

Superb Excellence is all I can say about this Company and its products. I will continue to buy from this company. The service is excellent and the product matches the service. Thanks for the great product and service. I will be ordering from you really soon.

—— Brant huges

Love it I’ve been using it for a long time

—— Drew

I'm Online Chat Now
Company News
Dapagliflozin Approved For Chronic Kidney Disease Indications
Latest company news about Dapagliflozin Approved For Chronic Kidney Disease Indications

Recently, AstraZeneca's SGLT2 inhibitor "dapagliflozin tablets" received approval for a new indication for adult patients with chronic kidney disease (CKD) at risk of disease progression (regardless of whether these patients have type 2 diabetes) , to reduce the estimated risk of persistent decline in glomerular filtration rate, progression to end-stage renal disease, cardiovascular death, and heart failure hospitalization.

 

Dapagliflozin is the first sodium-glucose cotransporter-2 (SGLT2) inhibitor, which is administered orally once daily. It is currently approved for 4 indications globally: type 1 diabetes, type 2 diabetes, and heart disease with reduced ejection fraction. aging and chronic kidney disease. In China, dapagliflozin was first approved in March 2017 for the treatment of type 2 diabetes, and has since been approved for heart failure with reduced ejection fraction and chronic kidney disease.

Pub Time : 2022-10-17 09:49:57 >> News list
Contact Details
Wuhan Senwayer Century Chemical Co., Ltd.

Contact Person: Mrs. Angie Zhang

Tel: +8613627115097

Fax: 86-27-5970-7018

Send your inquiry directly to us (0 / 3000)